Ann: Phase 3 Study in FSGS Kidney Patients Commences, page-21

Hi Dyeman,

While you are right, Spartensan an Endothelin A Receptor Blocker & ARB both block AT1-R they are slightly different drug classes. (Sparsentan a dual endothelin & angiotensin receptor blocker) there was also Atrasentan (an endothelin receptor blocker).

If we remember back to March 2021 & DMX-200 looking into Sparsentan & DMX-200 in vitro, they filed a new patent. I guess this will have greater importance to us now with what has recently (and positively) occurred for Travere, with the Vifor licencing deal.

Something that I remember some saw as insignificant & a few tiffs here at that time with the usually “it’s nothing” negativity.

Well it may be something very significant now in more ways than just DMX-200 as an adjunct to a therapy that has just moved into quite a substantial licencing deal with a Swiss International BP, but also the importance of both these inflammatory pathways in COVID-19 as well as kidney diseases (CKD/DKD).

AND that it looks like a newer class of drug (which is showing greater efficacy in Ph3 trials over ARB & is interchangeable with ARB & synergy with DMX-200, the potential for DMX-200 to enhance efficacy of these newer drugs as an adjunct therapy, by a different mechanism of targeting CCR2 inhibition.

I have screen shot the ANN. Be better than trying to post points, plus I need to get dinner on, hungry tribe!

Patent number is there & priority date of March 2021. I will take another look later tonight, but maybe you may get some time before I do Dyeman. I hope you are keeping well & life is treating you kindly. x

GLTAH.